Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase...
COVID-19
BioSig to Highlight New Data from the PURE EP™ Platform at Heart Rhythm 2023
Leading physicians from Cleveland Clinic to present data from three posters that showcase the Company’s novel PURE EP™ PlatformWestport, CT,...
Microbot Medical’s LIBERTY® Robotic System Surpasses 100th Catheterization
95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studiesHINGHAM, Mass., May 03, 2023...
Surgalign To Collaborate with Dr. Alexander Vaccaro and Dr. Pierce Nunley to Advance HOLO™ AI Insights and its Artificial Intelligence Technologies
DEERFIELD, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on...
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV...
NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes
Evo sEEGs complementary to Zimmer Biomet’s robotic neurosurgery platform; strong market opportunity for paired technologies EDEN PRAIRIE, Minn., May 02,...
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on...
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
FARMINGTON HILLS, Mich., May 02, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused...
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team...
Nanox.ARC Imaging System Receives FDA Clearance, Pioneering a New Era in Medical Imaging
Nanox.ARC Image of the Nanox ARC Nanox.ARC Image of the Nanox ARCNanox.ARC presents high powered digital X-ray tubes for 3D...
New GIMOTI Patent Listed in FDA Orange Book
Broad Formulation Patent Expands Protection for GimotiSOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty...
Nanox Files 2022 Annual Report on Form 20-F
NEVE ILAN, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical...
Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing
MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a...
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the...
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has...
Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights
Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two...
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients...
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
NASHUA, N.H., May 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer...